Valuation: Patrys Limited

Market Cap 23.33M 16.19M 14.18M 13.06M 12.12M 23.02M 1.54B 156M 60.84M 758M 60.8M 59.47M 2.63B P/E 2024
-4.06x
P/E 2025 -0.68x
Enterprise Value 22.59M 15.67M 13.73M 12.64M 11.74M 22.29M 1.5B 151M 58.9M 734M 58.87M 57.57M 2.54B EV / Sales 2024
8.72x
EV / Sales 2025 1.96x
Free-Float
99.37%
Yield 2024 *
-
Yield 2025 -
1 day-2.56%
1 week+8.57%
Current month+8.57%
1 month-9.52%
3 months+46.15%
6 months+40.74%
Current year+35.71%
1 week 0.04
Extreme 0.035
0.04
1 month 0.03
Extreme 0.034
0.05
Current year 0.02
Extreme 0.025
0.05
1 year 0.01
Extreme 0.012
0.05
3 years 0.01
Extreme 0.012
0.14
5 years 0.01
Extreme 0.012
0.72
10 years 0.01
Extreme 0.012
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap.
11/08/23Expiration

Chief Executive Officer

3,283 0.0002%
11/08/23Expiration

Chief Executive Officer

396,132 0.0193%
06/12/21Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
-2.56%+8.57%+111.11%-68.33% 18.04M
-0.37%-0.17%+73.86%+132.62% 57.73B
-0.93%-2.54%+73.64%+93.71% 54.69B
-3.71%-0.35%-14.61%-11.19% 23.75B
-0.05%+6.49%+14.05%+451.36% 24.18B
-2.70%+6.30%+46.83%-2.70% 19.82B
+2.49%+4.18%+42.97%-27.27% 17.14B
+3.58%+13.78%+196.41%+348.55% 16.75B
-1.81%+17.84%+45.86% - 15.57B
-0.57%+2.30%+20.33%+187.27% 13.96B
Average -0.66%+5.76%+61.04%+122.67% 24.36B
Weighted average by Cap. -0.61%+4.15%+58.45%+137.52%

Financials

2024 2025
Net sales 1.39M 967K 847K 780K 724K 1.38M 92.28M 9.34M 3.64M 45.3M 3.63M 3.55M 157M 829K 575K 504K 464K 430K 817K 54.84M 5.55M 2.16M 26.92M 2.16M 2.11M 93.33M
Net income -3.54M -2.46M -2.15M -1.98M -1.84M -3.49M -234M -23.71M -9.23M -115M -9.22M -9.02M -399M -3.01M -2.09M -1.83M -1.69M -1.57M -2.97M -199M -20.19M -7.86M -97.9M -7.85M -7.68M -339M
Net Debt -2.24M -1.55M -1.36M -1.25M -1.16M -2.21M -148M -15.01M -5.84M -72.8M -5.84M -5.71M -252M -742K -515K -451K -416K -386K -733K -49.14M -4.97M -1.94M -24.12M -1.93M -1.89M -83.64M
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
07/07/26 A$0.0380 -2.56% 97,108
06/07/26 A$0.0390 0.00% 12,169
03/07/26 A$0.0390 0.00% 594,445
02/07/26 A$0.0390 +8.33% 75,306
01/07/26 A$0.0360 +2.86% 105,593